Growth Metrics

Gilead Sciences (GILD) Shareholder's Equity (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 3.58%
Dec 31, 2025 5.40%
Sep 30, 2025 9.95%
Jun 30, 2025 2.68%
Mar 31, 2025 -0.87%
Dec 31, 2024 4.65%
Sep 30, 2024 1.06%
Jun 30, 2024 4.25%
Mar 31, 2024 -23.27%
Dec 31, 2023 2.28%
Sep 30, 2023 5.44%
Jun 30, 2023 0.74%
Mar 31, 2023 -1.27%
Dec 31, 2022 0.72%
Sep 30, 2022 4.17%
Jun 30, 2022 1.51%
Mar 31, 2022 -5.45%
Dec 31, 2021 -1.90%
Sep 30, 2021 8.93%
Jun 30, 2021 3.93%
Mar 31, 2021 4.08%
Dec 31, 2020 4.29%
Sep 30, 2020 -3.70%
Jun 30, 2020 -18.20%
Mar 31, 2020 -2.08%
Dec 31, 2019 9.23%
Sep 30, 2019 -8.86%
Jun 30, 2019 2.99%
Mar 31, 2019 2.59%
Dec 31, 2018 -6.40%
Sep 30, 2018 5.86%
Jun 30, 2018 5.24%
Mar 31, 2018 0.73%
Dec 31, 2017 -17.48%
Sep 30, 2017 7.60%
Jun 30, 2017 12.96%
Mar 31, 2017 5.57%
Dec 31, 2016 14.79%
Sep 30, 2016 4.67%
Jun 30, 2016 14.95%
Mar 31, 2016 -26.65%
Dec 31, 2015 9.76%
Sep 30, 2015 4.69%
Jun 30, 2015 -3.18%
Mar 31, 2015 8.60%
Dec 31, 2014 14.10%
Sep 30, 2014 -15.62%
Jun 30, 2014 22.72%
Mar 31, 2014 13.98%
Dec 31, 2013 7.91%
Sep 30, 2013 -1.88%
Jun 30, 2013 6.73%
Mar 31, 2013 8.89%
Dec 31, 2012 10.93%
Sep 30, 2012 7.52%
Jun 30, 2012 9.41%
Mar 31, 2012 6.50%
Dec 31, 2011 10.17%
Sep 30, 2011 3.08%
Jun 30, 2011 -2.08%
Mar 31, 2011 0.87%
Dec 31, 2010 7.28%
Mar 31, 2010 15.33%
Dec 31, 2009 15.21%
Sep 30, 2009 6.26%